<DOC>
	<DOC>NCT02055976</DOC>
	<brief_summary>The purpose of this study is to evaluate the low density lipoprotein cholesterol (LDL-C) lowering effect of Bococizumab (PF-04950615;RN316) administered subcutaneously at every two weeks (Q14D) in hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin, or who are naïve to a treatment by lipid lowering drug and whose LDL-C is not controlled.</brief_summary>
	<brief_title>Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Subjects whose LDLC is not controlled by a stable dose of atorvastatin (Population A). Subjects who are naïve to a treatment by lipid lowering drug and whose LDLC is not controlled (Population B). Severe acute or chronic medical or psychiatric condition or laboratory abnormality. Pregnant females; breastfeeding females; males and females of childbearing potential; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception. Subjects who were administered or prior exposed to PF04950615 and/or antibody targeting PCSK9.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PF-04950615</keyword>
	<keyword>Japan</keyword>
</DOC>